SCHEMBL501357

SCHEMBL501357

Cc1cc(C(C)(C)O[SiH2]C(C)(C)C)ccn1

nearest known ligand 0.39

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
UHRF1 Q96T88 1/20 0.39
DYRK1A Q13627 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5312279 0.81 RECQL (0.33)
SCHEMBL331282 0.81 NOS3 (0.49) DYRK1A
SCHEMBL1166696 0.81 AR (0.34)
SCHEMBL20320561 0.78 UHRF1 (0.45) UHRF1DYRK1A
SCHEMBL1166724 0.76 ALDH1A1 (0.38)
SCHEMBL2529902 0.76 KIF11 (0.38)
SCHEMBL2397909 0.74
SCHEMBL1535656 0.74 KMT2A (0.33)
SCHEMBL84569 0.73 UHRF1 (0.52) UHRF1DYRK1A
SCHEMBL1166763 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130005721-A1 INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE PANMIRA PHARMACEUTICALS, LLC (US) 2013-01-03 US disclosed
EP-2480547-A2 INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE Panmira Pharmaceuticals, LLC (US) 2012-08-01 EP disclosed
US-8106064-B2 administering 1-[2-Chloro-6-(4-methoxy-benzylamino)-pyridin-4-ylmethyl]-6-(3-[1,3]dioxolan-2-yl-5-methyl-phenoxy)-5-isopropyl-1H-pyrimidine-2,4-dione viricide to treat AIDS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-01-31 US disclosed
WO-2011038086-A2 INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE AMIRA PHARMACEUTICALS, INC. (US) 2011-03-31 WO disclosed
US-20100034827-A1 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS GILEAD SCIENCES, INC. (US) 2010-02-11 US disclosed
EP-2044037-A2 HIV REVERSE TRANSCRIPTASE INHIBITORS Gilead Sciences, Inc. (US) 2009-04-08 EP disclosed
US-20080070920-A1 Novel HIV reverse transcriptase inhibitors KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-03-20 US disclosed
WO-2008016522-A2 HIV REVERSE TRANSCRIPTASE INHIBITORS GILEAD SCIENCES, INC. (US) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005721-A1 INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE ALOX5, ALOX15, ALOX15B UHRF1 3079/4885DYRK1A 2943/4885
US-20100034827-A1 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS POLR2E, POLRMT, POLR2H UHRF1 3525/4885DYRK1A 4359/4885
US-20080070920-A1 Novel HIV reverse transcriptase inhibitors POLR2E, POLRMT, POLR2H UHRF1 3472/4885DYRK1A 4352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.